logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5209.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5209.produseast1
Journal Article
|Research

First-Line Antiretroviral Drug Discontinuations in Children

Fortuin-de Smidt M, de Waal R, Cohen K, Technau KG, Stinson K, Maartens G, Boulle AM, Igumbor EU, Davies MA
Download

Similar Content
Loading...
Loading...
Loading...
First-Line Antiretroviral Drug Discontinuations in Children | Journal Article / Research | MSF Science Portal
Abstract
There are a limited number of paediatric antiretroviral drug options. Characterising the long term safety and durability of different antiretrovirals in children is important to optimise management of HIV infected children and to determine the estimated need for alternative drugs in paediatric regimens. We describe first-line antiretroviral therapy (ART) durability and reasons for discontinuations in children at two South African ART programmes, where lopinavir/ritonavir has been recommended for children <3 years old since 2004, and abacavir replaced stavudine as the preferred nucleoside reverse transcriptase inhibitor in 2010.

Subject Area

pediatricsHIV/AIDS

Languages

English
Published Date
13 Feb 2017
PubMed ID
28192529
Journal
PLOS One
Volume | Issue | Pages
Volume null Issue 2
Issue Date
2017-02-13